Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

@article{Fennell2004DefectiveCS,
  title={Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.},
  author={D. A. Fennell and Robin Michael Rudd},
  journal={The Lancet. Oncology},
  year={2004},
  volume={5 6},
  pages={354-62}
}
Because of a lack of effective treatments, survival from diffuse pleural mesothelioma remains poor. Many people do not think that treatments for this disease are effective. The understanding of the biology of mesothelioma relevant to the apoptosis-resistant phenotype has been slow to advance. However, this is now changing, and strategies for rational therapeutic drug development are emerging that have the potential to change the natural history and improve survival in the increasing number of… CONTINUE READING